Recruiting
Phase 1
Phase 2

IPN60300

Sponsor:

Ipsen

Code:

NCT07213817

Conditions

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IPN60300

Study Details

Brief summary:

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection.

Study Phases:

  • Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose).
  • Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance).

Study Periods:

Screening: Up to 28 days before first IPN60300 injection to determine eligibility.

Treatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor.

Participants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.

Conditions

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Study ID

NCT07213817

Start date

Dec 5, 2025

Status verified date

Aug, 2026

Completion date

Oct 30, 2028

Anticipated

Primary completion date

Oct 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion criteria:

  • Participant must be ≥18 years of age, at the time of signing the informed consent.
  • Participants with histologically or cytologically documented, locally advanced, or metastatic solid tumors, that relapsed or were refractory after being previously treated with standard of care therapy; or for which there is no available established therapy; or standard therapy is contraindicated or not deemed appropriate by the treating investigator.
  • Participants must have measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Male and female participants Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Adequate bone marrow function within 7 days before first dose of study intervention,
  • Adequate renal function within 7 days before first dose of study intervention,
  • Adequate hepatic function or laboratory abnormalities indicating hepatic injury within 7 days before first dose of study intervention,
  • Prothrombin time or international normalised ratio (INR) ≤1.5 × ULN.
  • At the time of screening, a tumour tissue specimen is required for enrolment into the dose escalation and dose optimisation portions of the study for retrospective central laboratory determination.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Have a life expectancy of more than 3 months for disease-related mortality, as evaluated by the investigator.

Exclusion Criteria:

  • Known second malignancy either progressing or requiring active treatment within the last 2 years prior to first dose of study intervention.
  • Residual toxicity from prior anticancer therapy that are NCI CTCAE version 5.0 Grade 2 or higher. Stable chronic Grade 2 toxicities from previous treatments may be eligible per the judgement of investigator.
  • History of major surgery within 4 weeks prior to the first dose of study intervention.
  • Previous solid organ transplantation.
  • Pre-existing, acute or chronic severe corneal disorders, sequelae from severe corneal disorders, or a history of corneal transplantation.
  • Active brain metastases or leptomeningeal metastases with exception to asymptomatic and treated brain metastases (i.e. no neurological symptoms, no requirements for corticosteroids and lesions <1.5 cm), which are stable and not expected to become symptomatic in the next 3 months in the opinion of the investigator.
  • History of stroke or significant cerebrovascular disease (ie, transient ischemic attack) within 6 months prior to initiation of study intervention.
  • History of clinically significant cardiac disease within 6 months prior to the initiation of study intervention, including but not limited to unstable angina, acute myocardial infarction, endoscopic or open-heart cardiac surgery, or heart failure classified as New York Heart Association Grade 2 or higher.
  • History of clinically significant respiratory disease within 6 months prior to the initiation of study intervention, including severe chronic obstructive pulmonary disease or asthma.
  • History of noninfectious interstitial lung disease (ILD)/pneumonitis/radiation pneumonitis that required steroids or has current ILD/pneumonitis.
  • Clinically significant gastrointestinal disorder including bleeding, occlusion, diarrhoea >Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction.
  • Any evidence of severe active infection or inflammatory condition.
  • Significant concurrent, uncontrolled medical condition that would put participants at unacceptable risk from study participation or preclude them from complying with study procedures as per investigator assessment, including, but not limited to renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
  • Participants with uncontrolled human immunodeficiency virus (HIV). HIV infected participants are eligible if they meet criteria described in the protocol.
  • Known active infection with hepatitis B virus (HBV) OR hepatitis C virus (HCV). Participants are eligible if they meet criteria described in the protocol.
  • Ongoing immunosuppressive therapy, including systemic corticosteroids. NOTE: Physiologic replacement or use of topical or inhaled corticosteroids are allowed.
  • Concurrent participation in another therapeutic treatment trial, previous participation should respect the minimum of 5 half-lives or 4 weeks before the study intervention initiation (whichever is shorter).
  • Participants accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.
  • For French participants only: participants are under court protection, not affiliated to a social security system or protected adults.

Study Design

Enrollment

114 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Phase Ia: Dose escalation

IPN60300 will be administered at assigned dose level.

experimental: Phase Ib : Dose optimisation

Participants will be randomised to one of the two doses of interest.

Interventions

IPN60300

IPN60300 will be administered at assigned dose level.

Primary outcome measure

  • Phase Ia: Percentage of participants with dose limiting toxicity (DLT) [ Time Frame: within 21 days following study drug administration. ]
  • Phase Ia and Ib: Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TE SAEs). [ Time Frame: From the first IPN60300 administration until 30 days after the last dose ]
  • Phase Ib: Objective response rate (ORR) [ Time Frame: At end of study (up to approximately 3 years ) ]

Central Contacts and Locations

Central contacts

Ipsen Clinical Study Enquiries

See e mailclinical.trials@ipsen.com

Locations

Yale Cancer Center-Yale University

Recruiting

New Haven, Connecticut, United States, 06510

START Midwest

Recruiting

Grand Rapids, Michigan, United States, 49546

Sidney Kimmel Cancer Center

Recruiting

Philadelphia, Pennsylvania, United States, 19107

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

NEXT Oncology

Recruiting

San Antonio, Texas, United States, 78229

NEXT Oncology

Recruiting

Fairfax, Virginia, United States, 22031

More Information

Sponsor

Ipsen

Last update posted

Sep 1, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Ipsen on 2026-09-01.